Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Past, present, and future of entry inhibitors as HIV microbicides.

Gibson RM, Arts EJ.

Curr HIV Res. 2012 Jan 1;10(1):19-26. Review.

PMID:
22264042
2.

The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization.

Lovelace E, Xu H, Blish CA, Strong R, Overbaugh J.

Virology. 2011 Dec 20;421(2):235-44. doi: 10.1016/j.virol.2011.09.032. Epub 2011 Oct 24.

3.

Antigen-dependent and -independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection.

Haas A, Zimmermann K, Oxenius A.

J Virol. 2011 Dec;85(23):12102-13. doi: 10.1128/JVI.05607-11. Epub 2011 Aug 17. Review.

4.

Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition.

von Kleist L, Stahlschmidt W, Bulut H, Gromova K, Puchkov D, Robertson MJ, MacGregor KA, Tomilin N, Pechstein A, Chau N, Chircop M, Sakoff J, von Kries JP, Saenger W, Kräusslich HG, Shupliakov O, Robinson PJ, McCluskey A, Haucke V.

Cell. 2011 Aug 5;146(3):471-84. doi: 10.1016/j.cell.2011.06.025. Erratum in: Cell. 2011 Sep 2;146(5):841. Tomlin, Nikolay [corrected to Tomilin, Nikolay].

5.
6.

HIV-associated immune activation: from bench to bedside.

d'Ettorre G, Paiardini M, Ceccarelli G, Silvestri G, Vullo V.

AIDS Res Hum Retroviruses. 2011 Apr;27(4):355-64. doi: 10.1089/aid.2010.0342. Epub 2011 Mar 8. Review.

PMID:
21309730
7.

Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.

Wagoner J, Morishima C, Graf TN, Oberlies NH, Teissier E, Pécheur EI, Tavis JE, Polyak SJ.

PLoS One. 2011 Jan 28;6(1):e16464. doi: 10.1371/journal.pone.0016464.

8.

HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies.

Operskalski EA, Kovacs A.

Curr HIV/AIDS Rep. 2011 Mar;8(1):12-22. doi: 10.1007/s11904-010-0071-3. Review.

9.

Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C.

Beinhardt S, Rasoul-Rockenschaub S, Scherzer TM, Ferenci P.

J Hepatol. 2011 Mar;54(3):591-2; author reply 592-3. doi: 10.1016/j.jhep.2010.09.009. Epub 2010 Oct 14. No abstract available.

10.

Endocytosis of HIV: anything goes.

Permanyer M, Ballana E, Esté JA.

Trends Microbiol. 2010 Dec;18(12):543-51. doi: 10.1016/j.tim.2010.09.003. Epub 2010 Oct 19. Review.

PMID:
20965729
11.

Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient.

Payer BA, Reiberger T, Rutter K, Beinhardt S, Staettermayer AF, Peck-Radosavljevic M, Ferenci P.

J Clin Virol. 2010 Oct;49(2):131-3. doi: 10.1016/j.jcv.2010.07.006. Epub 2010 Aug 14.

PMID:
20709593
12.

Multiple effects of silymarin on the hepatitis C virus lifecycle.

Wagoner J, Negash A, Kane OJ, Martinez LE, Nahmias Y, Bourne N, Owen DM, Grove J, Brimacombe C, McKeating JA, Pécheur EI, Graf TN, Oberlies NH, Lohmann V, Cao F, Tavis JE, Polyak SJ.

Hepatology. 2010 Jun;51(6):1912-21. doi: 10.1002/hep.23587.

13.

Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy.

Neumann UP, Biermer M, Eurich D, Neuhaus P, Berg T.

J Hepatol. 2010 Jun;52(6):951-2. doi: 10.1016/j.jhep.2010.02.002. Epub 2010 Mar 15. No abstract available.

14.

Identification of hepatoprotective flavonolignans from silymarin.

Polyak SJ, Morishima C, Lohmann V, Pal S, Lee DY, Liu Y, Graf TN, Oberlies NH.

Proc Natl Acad Sci U S A. 2010 Mar 30;107(13):5995-9. doi: 10.1073/pnas.0914009107. Epub 2010 Mar 15.

15.

Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.

Ahmed-Belkacem A, Ahnou N, Barbotte L, Wychowski C, Pallier C, Brillet R, Pohl RT, Pawlotsky JM.

Gastroenterology. 2010 Mar;138(3):1112-22. doi: 10.1053/j.gastro.2009.11.053. Epub 2009 Dec 4.

PMID:
19962982
16.

Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection.

Morishima C, Shuhart MC, Wang CC, Paschal DM, Apodaca MC, Liu Y, Sloan DD, Graf TN, Oberlies NH, Lee DY, Jerome KR, Polyak SJ.

Gastroenterology. 2010 Feb;138(2):671-81, 681.e1-2. doi: 10.1053/j.gastro.2009.09.021. Epub 2009 Sep 24.

17.

Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.

Macías J, Berenguer J, Japón MA, Girón JA, Rivero A, López-Cortés LF, Moreno A, González-Serrano M, Iribarren JA, Ortega E, Miralles P, Mira JA, Pineda JA.

Hepatology. 2009 Oct;50(4):1056-63. doi: 10.1002/hep.23136.

PMID:
19670415
18.

Coinfection with HIV-1 and HCV--a one-two punch.

Kim AY, Chung RT.

Gastroenterology. 2009 Sep;137(3):795-814. doi: 10.1053/j.gastro.2009.06.040. Epub 2009 Jun 21. Review.

19.

Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1.

Blish CA, Jalalian-Lechak Z, Rainwater S, Nguyen MA, Dogan OC, Overbaugh J.

J Virol. 2009 Aug;83(15):7783-8. doi: 10.1128/JVI.00673-09. Epub 2009 May 27.

20.

Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus.

Roe B, Hall WW.

Expert Rev Mol Med. 2008 Oct 20;10:e30. doi: 10.1017/S1462399408000847. Review.

PMID:
18928579
Items per page

Supplemental Content

Write to the Help Desk